Business model– Investing for Impact
Within each country investing for impact should place a specific focus on increasing domestic health financing with a specific focus on these three major disease burdens in Africa. To invest for impact we should ensure that available resources are targeted where the disease burden is highest.
Strategic information that stratifes disease incidence and prevalence at national, district and community levels is critical in enabling appropriate targeting of interventions and more effective investment.
Specifically investing for impact on AIDS, TB and Malaria consists of three strategic investment areas (each with clear catalytic actions).
- Strategic investment area one: Health systems strengthening;
- Strategic investment area two: Generation and use of evidence for policy and programme interventions;
- Strategic investment area three: Advocacy and capacity building.
Strategic investment area one: Health Systems Strengthening
Prioritise and scale up the following elements of health systems to catalyse actions to end the three diseases:
- Diversified and Innovative Domestic Financing for Health including putting in place clear efficiency gains measures;
- Health Management Information Systems (HMIS) and surveillance through data quality monitoring and improvement;
- Procurement and supply management systems audit and strengthening;
- Strategic & operational planning strengthening at national/district levels;
- Human resource mobilisation, management, absorptive capacity monitoring and improvement.
- Provision of appropriate technologies and equipment.
- Health workforce training, deployment and retention.
Strategic investment area two: Generation and use of evidence for policy and programme interventions
Prioritise generation and use of evidence for catalysing actions to end the three diseases through:
- Regular household surveys for HIV; TB and Malaria;
- Annual data peer review and surveillance strengthening meetings at various levels;
- Development and dissemination of annual country outlook based on available data with focus on tailored interventions based on evidence;
- Annual, mid-term and end-term programme reviews;
- Special studies and operational researches including drug and vector resistance;
- monitoring and vector bionomics studies;
- Documentation and dissemination of best practices;
- Strengthen reporting and availability of data for National Health Accounts including government allocated funds, donor & private sector contributions.
- Promote and strengthen financing for Reseach and Development & Innovation at continental, regional, national and local levels.
Strategic investment area three: Advocacy and capacity building
Prioritise catalytic actions that create an enabling environment and build competencies to end the three diseases through:
- Champion sustainable political will, ownership and accountability;
- Training of health workers in key priority areas including stratification and programme management;
- Development and adoption of appropriate implementation guidelines and tools;
- Consultative and information sharing platforms for health workers;
- Development and adoption of appropriate norms and standards.